74 studies on Semax curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Peptaris | 19 | 99.29% | View COA → |
| Unknown vendor (review) | 11 | 99.49% | View COA → |
| Elite Research | 9 | 99.23% | View COA → |
| Oath Research | 8 | 99.42% | View COA → |
| Felix Chemical Supply | 8 | 99.14% | View COA → |
| Allen Biotechnology Co Abc | 7 | 99.83% | View COA → |
| Gulf Coast Amino Acids | 6 | 99.47% | View COA → |
| Path Peptides | 6 | 99.41% | View COA → |
Recent certificates: #27999 (99.83%) · #32739 (99.67%) · #45595 (99.74%) · #27955 (99.47%) · #41475 (99.94%) · #51588 (99.66%)
Manufacturers with published third-party certificates of analysis for Semax. Open a vendor to see every batch we've verified.
This research highlights PGC-1α activation as a promising therapeutic strategy for mitigating brain damage following ischemic stroke. By enhancing mitochondrial function and reducing oxidative stress, PGC-1α activator…
This research provides strong molecular evidence for Semax's neuroprotective properties, specifically its ability to mitigate the detrimental inflammatory response after ischemic stroke. By suppressing the mRNA expres…
This study provides critical molecular evidence supporting ACTH's neuroprotective role by elucidating its impact on the brain's protein landscape. The upregulation of neurotrophic factors like BDNF and downregulation …
This research highlights that melanocortin derivatives show substantial promise as potential therapeutic agents for mitigating the impact of stress and treating stress-related disorders. By actively normalizing gene e…
This study successfully establishes a robust and reproducible mouse model for nigrostriatal dopaminergic axonal degeneration, providing a critical tool for preclinical drug discovery. This model offers a high-throughp…
This study highlights Semax's potential as a therapeutic agent for Alzheimer's disease by directly targeting copper-mediated Abeta toxicity, a key pathway in neurodegeneration. Its ability to interfere with a critical…
This research underscores the transformative potential of 3-D Shear Wave Elastography as a superior, non-invasive diagnostic tool for thyroid nodules. The significantly improved accuracy, sensitivity, and specificity …
This research is significant because it suggests that complex physiotherapeutic neurostimulation could offer a novel, non-invasive therapeutic strategy for a range of optical neuropathies, conditions for which effecti…
This study provides compelling evidence that synthetic corticotropins can directly and indirectly modulate the GABA-receptor system, offering a novel therapeutic avenue for stress-related neuropsychiatric disorders. T…
This study's findings are significant because they suggest synthetic ACTH peptides could be a novel therapeutic strategy to mitigate detrimental neuroinflammation after stroke. By shifting the immune response towards …
These findings provide critical insights into the molecular mechanisms underlying the neuroprotective and cognitive-enhancing effects of synthetic ACTH-like peptides. The significant upregulation of genes vital for ne…
These findings are significant as they identify Semax and Melanotan II as promising candidates for treating stress-related disorders and depression, potentially offering a new class of neuroactive peptides. Their abil…
This breakthrough represents a significant advancement in multifunctional material design, offering a robust solution for diverse high-tech applications. The ability to combine high EMI shielding with excellent mechan…
This research highlights the significant neuroprotective and gene-regulatory potential of ACTH-like peptides in the context of ischemic stroke. By restoring a vast majority of disrupted gene expression profiles, these…
This research highlights Semax's potential as a neuroprotective agent against key aspects of Alzheimer's disease (AD) pathology. By targeting metal-induced oxidative stress, Semax offers a novel therapeutic strategy t…
This research uncovers a novel mechanism by which Semax peptide promotes recovery after spinal cord injury, specifically through targeting the Oprm1 gene and enhancing deubiquitination, a process crucial for protein s…
These findings provide crucial insights into the cellular targets and initial interaction dynamics of Semax within the brain, particularly highlighting its specific impact on hippocampal neurons. The observed increase…
This research highlights the potential of ACTH4-10Pro8-Gly9-Pro10 to actively promote an anti-inflammatory response in the acute phase of spinal cord injury, which is critical for limiting secondary damage. By boostin…
This research highlights the potential of Selank as a therapeutic agent for managing non-motor symptoms, specifically anxiety, in Parkinson's disease, even in the presence of significant neurodegeneration. The fact th…
The analysis successfully identified multiple instances of various putative cognitive enhancing research peptides within the seized preparations. Specifically, well-known compounds such as Noopept, Semax, and Selank w…
This research provides crucial insights into the neurobiological mechanisms underlying the known anxiolytic and nootropic effects of Selank and Semax. Understanding how these peptides modulate specific brain networks …
These compelling results indicate that Semax possesses significant neuroprotective and cognitive-enhancing properties in a relevant animal model of ischemic stroke. The observed reductions in infarct volume and improv…
This research highlights the significant therapeutic potential of Semax and its derivative as novel treatments for Alzheimer's disease. The observed improvements in cognitive function, reduction in neuroinflammation, …
Free, no account — handy when you're working with Semax.